Palbociclib Plus Fulvestrant or Everolimus Plus Exemestane for Pretreated Advanced Breast Cancer with Lobular Histotype in ER+/HER2− Patients: A Propensity Score-Matched Analysis of a Multicenter Retrospective Patient Series †

Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in combination with endocrine therapy (ET) show meaningful efficacy and tolerability in patients with metastatic breast cancer (MBC), but the optimal sequence of ET has not been established. It is not clear if patients with lobular breast carcinomas (...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Pers Med
Main Authors: Orlandi, Armando, Iattoni, Elena, Pizzuti, Laura, Fabbri, Agnese, Botticelli, Andrea, Di Dio, Carmela, Palazzo, Antonella, Garufi, Giovanna, Indellicati, Giulia, Alesini, Daniele, Carbognin, Luisa, Paris, Ida, Vaccaro, Angela, Moscetti, Luca, Fabi, Alessandra, Magri, Valentina, Naso, Giuseppe, Cassano, Alessandra, Vici, Patrizia, Giannarelli, Diana, Franceschini, Gianluca, Marchetti, Paolo, Bria, Emilio, Tortora, Giampaolo
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7766166/
https://ncbi.nlm.nih.gov/pubmed/33353132
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jpm10040291
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados